PhRMA comments to USTR on ACTA  Written by James Love Wednesday,
09 July 2008   March 21, 2008  By E-Mail  Office of the U.S.
Trade Representative 600 17th Street, N.W.  Washington, D.C.
20508  Attention: Rachel Bae  Re: Anti-Counterfeiting Trade
Agreement - PhRMA Response to Request for Written Comments 73
Fed. Reg. 8910 (Feb. 15, 2008)  Dear Ms. Bae:  The
Pharmaceutical Manufacturers of America (PhRMA) appreciates the
opportunity to comment on the Anti-Counterfeiting Trade
Agreement ("ACTA") in response to the above­ referenced Federal
Register notice. As a representative of America's leading
research-based pharmaceutical and biotechnology companies, PhRMA
strongly supports' the objectives of ACTA and urges USTR to
develop a framework of commitments that will serve as a gold
standard for pharmaceutical anti -counterfeiting enforcement
efforts throughout the world.  I. Background on Pharmaceutical
Counterfeiting  Counterfeit medical products are manufactured,
marketed and sold with the deliberate intent to d